


Carragelose®

The basis for antiviral therapies



Company highlights



Innovative biopharmaceutical company focused on respiratory, allergy and ophthalmic OTC and Rx therapies

1

Established biopharmaceutical company with a global presence

- Unique, asset-light business model with significant growth potential
- Significant pipeline with multiple, derisked and near to market assets
- Strong experience with bringing products to market

2

Carragelose®: a powerful OTC platform focused on respiratory diseases

- Clinically proven efficacy against over 200 viral strains
- Six products on the market, generating approximately €25m in retail sales in over 40 countries
- Significant growth potential with additional near term (new) product launches in major markets

3

Marinosolv®: an innovative drug delivery platform focused on allergy and eye diseases

- Enabling novel stable aqueous formulations of hardly soluble compounds
- Budesolv in Phase III for allergic rhinitis, Tacrosolv in Phase II for allergic conjunctivitis/dry eye
- Potential for additional indications through proprietary programs and/or Pharma licensing deals

4


Experienced leadership team backed by high quality boards

- Strong track record in the pharmaceutical industry and scientific community
- Over €65m in total equity and non-dilutive funding raised to date
- Backed by a renowned Scientific Advisory Board

Paradigm today



There is no broad anti-viral treatment or vaccination against more than 200 different respiratory virus strains:

- Coronavirus
- Rhinovirus
- Parainfluenza virus
- Metapneumovirus
- Respiratory syncytial virus
- Influenza virus
- Adenovirus



These viruses cause or worsen important diseases!

Virus associated indications




Indirect indications means diseases that are potentially worsened due to respiratory viral infections, such as asthma, allergic rhinitis, lung transplantation and COPD

Carragelose[®], the basis for antiviral therapies





Technology platform for developing therapies targeting over 200 respiratory viral strains





Unique mode of action

Carragelose® blocks viral attachment to cells via an unspecific physical mechanism



Carragelose®





Colds are caused by more than 200 different respiratory viruses

Cold viruses bind to the surfaces of the upper respiratory tract, initiating the infection

Preservative- and sugar-free. Can be used from an age of 1 year as well as during pregnancy and lactation

Carragelose® creates a protective layer that reduces the spreading and proliferation of the common cold virus

Clotted viruses leave the body via the natural route → cold is either prevented or is significantly shorter in duration



Carragelose® creates a protective physical barrier on the nasal and oral mucosa thus preventing binding and / or entry of the respiratory viruses into the cells


Clinically validated

Efficacy of Carragelose[®] platform has been clinically proven in children and adults



Carragelose[®] → clinically proven to reduce cold symptoms and duration

- 3 Double-blind, placebo-controlled clinical trials in a natural setting conducted with Carragelose
- 450 Patients enrolled of which >150 children with an average age of four years
- 1.2 mg/ml Carragelose[®], 0.5% NaCl in water three times daily versus a placebo saline nasal spray
- 0.009 P value of reduction of viral load in nasal lavages, symptoms of common cold reduced with P = 0.046
- 0 treatment related serious adverse events and withdrawals due to adverse event development



The average duration of common cold disease in patients of different virus subgroups in days (* P<0.05, ** p<0.01)

Patients	Group	hRV (days)	hCV (days)	InfA (days)
ITT	Carrageenan	8.8 ± 0.6	9.02 ± 0.7	8.7 ± 1.0
	Placebo	10.7 ± 0.7	12.95 ± 0.99	12.0 ± 1.2
	Difference	1.9*	3.9**	3.3*
PP	Carrageenan	8.7 ± 0.7	9.1 ± 0.7	9 ± 1.1
	Placebo	10.5 ± 0.8	12.2 ± 1.1	10.7 ± 1.5
	Difference	1.8 days*	3.1 days**	1.7 days

Anti-viral effectiveness of Carragelose[®] was confirmed in all three clinical trials
 Significant reduction of the duration of the disease, viral load **and** relapses was shown


Source: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray, Respiratory Research 2010; Carrageenan nasal spray in virus confirmed common cold, Multidiscip Respir Med. 2014; 9(1): 57; Abbrev: hrV = human rhinovirus, hCV = coronavirus types OC43 and 229E, InfA = influenza virus type A

Carragelose® portfolio overview

Five products already on the market, more to be developed



Carragelose®



1 Nasal products

- Anti-viral nasal spray
- Anti-viral kids nasal spray
- Anti-viral cold/flu nasal spray
- Anti-viral decongestant nasal spray



Launched

2 Throat products

- Anti-viral lozenges
- Anti-viral throat spray



Launched

3 Lung products


- Inhalation product for viral lung infections

Launch TBD

The Carragelose® products focus on anti-viral protection and treatment of respiratory infections

Excellent traction with established brands

Carragelose® products are partnered with strong global partners



Marinomed's partners

- | | |
|------------|------------|
| (Multiple) | (Multiple) |
| (Multiple) | (DE) |
| (AUS/NZ) | (Canada) |
| (HU) | (AT) |
| (Baltics) | (Nordics) |
| (CH) | (GR) |



Carragelose® products generated approximately €25m in total retail sales globally in 2017

Carragelose[®]

The basis for antiviral therapies

Contact BD&L

renate.moser@marinomed.com

www.marinomed.com

